Record
stringlengths 1
197k
|
|---|
* Is there a greater decrease in IFN-γ, FOXP3+Treg, and NFĸB levels in lesions of patients with AGW given adjuvant oral nanocurcumin compared to controls?
|
* Is the decrease in IFN-γ, FOXP3+TReg, and NFĸB levels in lesions of patients with AGW, with adjunctive oral nanocurcumin administration in 90% TCA therapy, associated with the degree of clinical improvement in patients with AGW?
|
Participants will be divided into 2 groups. The first one was given capsules without active ingredients/nanocurcumin (control group), and the second one was given capsules with nanocurcumin (experimental group), both group received a dosage of 200mg capsules per day after breakfast, for 8 weeks. The researchers conducted a comparison between those 2 groups to assess whether the adjuvant administration of oral nanocurcumin in 90% TCA therapy enhances the proportion of clinical improvement in patients with AGW. conditions: Anogenital Wart studyType: INTERVENTIONAL phases: PHASE2 phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 78 type: ACTUAL name: Curcumin Oral Capsule name: Trichloroacetic acid name: Blood sample collection name: Cotton swab measure: Clinical improvement in patients with AGW measure: Level of IFN-γ in lesions of AGW patients measure: Level of FOXP3+Treg in lesions of AGW patients measure: Level of NFĸB in lesions of AGW patients sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Cipto Mangunkusumo Hospital city: Jakarta Pusat state: DKI Jakarta zip: 10430 country: Indonesia lat: -6.1818 lon: 106.8223 hasResults: False
|
<|newrecord|> nctId: NCT06281340 id: He-ankle US briefTitle: Changes in Intra-articular Parameters by Doppler Ultrasound in Patients With Hemophilic Ankle Arthropathy overallStatus: NOT_YET_RECRUITING date: 2024-02-28 date: 2024-04-10 date: 2024-04-21 date: 2024-02-28 date: 2024-02-28 name: Investigación en Hemofilia y Fisioterapia class: NETWORK briefSummary: Introduction: Hemophilic ankle arthropathy is manifested by functional degenerative alterations, intra-articular alterations, and chronic pain. Manual therapy techniques are used in the treatment of hemophilic ankle arthropathy for the improvement of pain and mobility.
|
Design. Double-blind randomized pilot trial. Aimed: To evaluate the ultrasound changes by means of Doppler imaging after manual therapy intervention.
|
Patients: A total of 20 adult patients with hemophilic ankle arthropathy will be recruited.
|
Intervention: Each manual therapy session will last approximately 50 minutes, with 1 session per week for a period of 3 weeks. The treatment program includes 10 techniques that will be administered bilaterally.
|
Measuring instruments: Patients will be evaluated qualitatively with ultrasound (HEAD-US scale) and assessment with Doppler ultrasound. The clinical variables will be joint damage (Hemophilia Joint Health Score) and pain intensity (Visual Analogue Scale).
|
Expected results: Check the safety of manual therapy in patients with hemophilia regarding subclinical bleeding. Assess changes related to joint inflammatory state with imaging techniques. Observe changes in pain intensity and joint damage. conditions: Hemophilia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: DIAGNOSTIC masking: DOUBLE maskingDescription: Randomization will be performed using a computerized randomization procedure by permuted blocks of 4 subjects in each recruitment center. The 6 possible sequence alternatives will be modified in each block. This task will be carried out by a person who is not involved in the study and who will not know the identity of the subjects. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 20 type: ESTIMATED name: Manual therapy name: Placebo therapy measure: Change from baseline sonographic changes after 4 hours measure: Change from baseline joint pain after 4 hours measure: Change from baseline joint damage after 4 hours measure: Change from baseline degree of joint inflammation after 4 hours sex: MALE minimumAge: 30 Years maximumAge: 55 Years stdAges: ADULT facility: University of Oviedo city: Oviedo state: Asturias zip: 33006 country: Spain lat: 43.36029 lon: -5.84476 hasResults: False
|
<|newrecord|> nctId: NCT06281327 id: TX-ITP-001 briefTitle: Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia overallStatus: RECRUITING date: 2024-03 date: 2025-12 date: 2025-12 date: 2024-02-28 date: 2024-02-28 name: Institute of Hematology & Blood Diseases Hospital, China class: OTHER name: Henan Cancer Hospital name: Tianjin Medical University Second Hospital name: Tianjin Children's Hospital name: The Second Affiliated Hospital of Kunming Medical University briefSummary: To evaluate the safety and efficacy of avatrombopag in the treatment of pediatric primary immune thrombocytopenia in patients who have been treated with eltrombopag before and switched to avatrobopag because of poor efficacy, excessive platelet fluctuation or intolerance, or patient preference, economic reasons, and other reasons. conditions: Immune Thrombocytopenia conditions: Treatment studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 60 type: ESTIMATED name: Avatrombopag measure: Overall efficacy response after AVA treatment within 12 weeks measure: Treatment response-1 measure: Treatment response-2 measure: Time to Response measure: Persistent response measure: Emergency treatment measure: Reduction of concomitant drug measure: Number of participants with clinically significant bleeding as assessed using the world health organization (WHO) bleeding scale. measure: Number of participants with clinically significant bleeding as assessed using the bleeding scale for pediatric patients with ITP. measure: Health-related quality of life survey of subjects(HRQoL)-1 measure: Health-related quality of life survey of subjects(HRQoL)-2 measure: Health-related quality of life survey of subjects(HRQoL)-3 measure: Health-related quality of life survey of subjects(HRQoL)-4 sex: ALL minimumAge: 6 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College status: RECRUITING city: Tianjin country: China name: Lei Zhang, MD role: CONTACT phone: +8602223909009 email: [email protected] name: Ting Sun, MD role: CONTACT phone: +8602223909009 email: [email protected] lat: 39.14222 lon: 117.17667 hasResults: False
|
<|newrecord|> nctId: NCT06281314 id: VESPA 2.0 briefTitle: The Efficacy of VESPA 2.0 for Cognitive Rehabilitation in Patients With Mild Cognitive Impairment overallStatus: COMPLETED date: 2021-03-01 date: 2022-12-27 date: 2023-12-31 date: 2024-02-28 date: 2024-03-08 name: IRCCS Centro Neurolesi "Bonino-Pulejo" class: OTHER briefSummary: VESPA 2.0 is based on an integrative and ecological approach used for the treatment of cognitive dysfunction in patients with MCI or other neurodegenerative disorders. conditions: Neurodegenerative Diseases conditions: Cognitive Decline conditions: Parkinson Disease Dementia conditions: Alzheimer Disease conditions: Multiple Sclerosis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 60 type: ACTUAL name: Vespa software measure: Montreal cognitive assessment (MoCA) sex: ALL minimumAge: 50 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS Centro Neurolesi Bonino Pulejo city: Messina state: Sicily zip: 98124 country: Italy lat: 38.19394 lon: 15.55256 hasResults: False
|
<|newrecord|> nctId: NCT06281301 id: HSC-MS-23-1023 briefTitle: Improving Patient Understanding of Macrosomia overallStatus: RECRUITING date: 2024-01-30 date: 2024-04-30 date: 2024-09-01 date: 2024-02-28 date: 2024-02-28 name: The University of Texas Health Science Center, Houston class: OTHER briefSummary: The purpose of this study is to evaluate the effectiveness of a graphic based education tool on patient knowledge of macrosomia through the use of a survey and to evaluate knowledge at 1-2 weeks after initial review of the education tool. conditions: Macrosomia, Fetal studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 176 type: ESTIMATED name: education tool name: no additional information measure: Number of participants that showed Macrosomia knowledge greater than 50 percent as assessed by the score on a survey sex: FEMALE minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: The University of Texas Health Science Center at Houston status: RECRUITING city: Houston state: Texas zip: 77030 country: United States name: Kristen Cagino, MD role: CONTACT phone: 713-500-6412 email: [email protected] name: Suneet Chauhan role: CONTACT email: [email protected] lat: 29.76328 lon: -95.36327 hasResults: False
|
<|newrecord|> nctId: NCT06281288 id: P.T.REC/012/004754 briefTitle: Cognitive-Behavioral Therapy With Exercise Training in Adolescent Females With Elevated Depression Symptoms overallStatus: ENROLLING_BY_INVITATION date: 2023-12-25 date: 2024-03 date: 2024-03 date: 2024-02-28 date: 2024-03-19 name: Doaa Tammam Atia class: OTHER briefSummary: PURPOSE: To Study the Effect of Cognitive-behavioral therapy combined with exercise training in adolescent females with elevated depression symptoms
|
BACKGROUND: Teenagers are more likely than any other age group to experience psychological issues due to depression, Adolescents have gotten active attention from society for their mental health difficulties since they are a high-level reserve talent stratum in society. Adolescent depression rates have increased in recent years, and "silent killers" are preying on them. Teenagers are more likely than any other age group to experience psychological issues due to depression, Adolescents have gotten active attention from society for their mental health difficulties since they are a high-level reserve talent stratum in society. Adolescent depression rates have increased in recent years, and "silent killers"
|
RESEARCH QUESTION: Is there is an effect of exercise on depression in adolescent girls. conditions: Depression studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: FACTORIAL primaryPurpose: PREVENTION masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Cognitive-Behavioral Therapy name: Exercise Training measure: Center for Epidemiological Studies Depression Scale for Children (CES-DC), sex: FEMALE minimumAge: 12 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: doaa Tammam Atia city: Suez country: Egypt lat: 29.97371 lon: 32.52627 hasResults: False
|
<|newrecord|> nctId: NCT06281275 id: TJ-IRB202402008 briefTitle: A Study of the Association Between Frailty and Acute Postoperative Pain in Elderly Thoracoscopic Surgery Patients overallStatus: NOT_YET_RECRUITING date: 2024-04-12 date: 2024-09-30 date: 2024-10-30 date: 2024-02-28 date: 2024-04-12 name: Huazhong University of Science and Technology class: OTHER briefSummary: To gain a clearer understanding of the association between frailty and postoperative acute pain in elderly thoracoscopic surgery patients and its underlying mechanisms, to provide new solution ideas to reduce the level of postoperative acute pain and improve the debilitating state of elderly thoracoscopic surgery patients, and consequently improve their quality of life and mental status. conditions: Frailty conditions: Acute Postoperative Pain studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 78 type: ESTIMATED measure: All patients' Numerical Rating Scale （NRS） scores for most significant pain at rest in the 48h postoperative period measure: Numerical Rating Scale （NRS） scores for the most pronounced pain in the patient's coughing state in the 48h postoperative period measure: PCA pump consumption measure: Number of PCA pump presses sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology city: Wuhan state: Hubei zip: 430030 country: China lat: 30.58333 lon: 114.26667 hasResults: False
|
<|newrecord|> nctId: NCT06281262 id: GIP-23-L-04-223 briefTitle: Selected Immunological Indicators and Microbiota in Patients With Premature Birth and Preeclampsia acronym: PRIME overallStatus: RECRUITING date: 2023-06-30 date: 2025-03-30 date: 2025-03-30 date: 2024-02-28 date: 2024-03-01 name: General University Hospital, Prague class: OTHER name: Charles University, Czech Republic name: Institute of Hematology and Blood Transfusion, Czech Republic briefSummary: The goal is to demonstrate the relationship of the circulating pool of T-regulatory lymphocytes in the mother's peripheral blood with populations in the placentas and to compare with controls, what is the difference in the expression of individual regulatory molecules of T-regulatory lymphocytes according to new paradigms. The proportional and functional characteristics of T-regulatory lymphocytes will be correlated with the composition of the intestinal and vaginal microbiota. conditions: Preterm Birth conditions: Preeclampsia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: Peripheral blood collection name: Swab sample collection measure: Changes in selected T cell subpopulations in the first trimester associated with subsequent spontaneous preterm birth measure: Changes in selected T cell subpopulations in the first trimester associated with subsequent pre-eclampsia measure: Association of maternal microbiota and maternal T regulatory cell populations. sex: FEMALE minimumAge: 19 Years maximumAge: 40 Years stdAges: ADULT facility: Department of Gynaecology, Obstetrics and Neonatology of the First Faculty of Medicine of the Charles University and General University Hospital in Prague status: RECRUITING city: Prague zip: 128 08 country: Czechia name: Zdeněk Laštůvka, MUDr., Ph.D. role: CONTACT phone: +420777724640 email: [email protected] name: Michal Koucký, Doc., MUDr., Ph.D. role: CONTACT phone: +420603219916 email: [email protected] lat: 50.08804 lon: 14.42076 hasResults: False
|
<|newrecord|> nctId: NCT06281249 id: 73172 briefTitle: Neuraxial Ultrasound Device Study overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-03 date: 2025-03 date: 2024-02-28 date: 2024-03-15 name: Stanford University class: OTHER name: Rivanna Medical, Inc. briefSummary: The aim of the study is to develop a device that can eliminate failed neuraxial placements in challenging patients.The study will attempt to improve safety and efficacy of neuraxial anesthesia with high precision real-time needle visualization through automated real-time needle guidance at the bedside with an experimental device (Accuro 3S). Investigators will verify the clinical workflow for utilizing the Accuro 3S during epidural and spinal procedures and validation of needle visualization while using the device as well as anatomical guidance provided by the device during spinal imaging.The underlying bone imaging enhancement algorithms were introduced in the commercially available FDA approved Accuro. The Accuro 3S will be used to establish needle insertion point and trajectory, after which the clinician will use standard of care methods to advance the needle such as the loss of resistance method. conditions: Labor Pain conditions: Cesarean Delivery Regional Anesthesia Induction studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 100 type: ESTIMATED name: Ultrasound placement device measure: Incidence of difficult block placement measure: Incidence of failed block measure: Incidence of post-dural puncture headache sex: FEMALE minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Stanford University city: Stanford state: California zip: 94305 country: United States lat: 37.42411 lon: -122.16608 hasResults: False
|
<|newrecord|> nctId: NCT06281236 id: SPI-62-CL-1002 briefTitle: A Trial of Prednisolone in Combination With SPI-62 in Participants With Polymyalgia Rheumatica (PMR) overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2024-10-01 date: 2024-10-01 date: 2024-02-28 date: 2024-02-28 name: Sparrow Pharmaceuticals class: INDUSTRY briefSummary: This will be an open label phase 1b trial to characterize the pharmacodynamics and PK of prednisolone and SPI-62 when co-administered to participants with PMR. Up to 24 participants could be recruited. conditions: Polymyalgia Rheumatica studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 24 type: ESTIMATED name: Prednisolone name: SPI-62 measure: Erythrocyte sedimentation rate measure: C-reactive protein measure: Plasma fibrinogen sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Emovis Gmbh city: Berlin country: Germany name: Anna Wieczorek role: CONTACT phone: +49 30 439741221 email: [email protected] name: Frank Zollmann role: PRINCIPAL_INVESTIGATOR lat: 52.52437 lon: 13.41053 facility: Klinische Forschung Hannover Mitte GmbH/Pratia city: Hannover zip: 30159 country: Germany name: Matilde Planer role: CONTACT phone: +49 511 169 7650 email: [email protected] name: Jan Wagner role: PRINCIPAL_INVESTIGATOR lat: 52.37052 lon: 9.73322 facility: Klinische Forschung Schwerin GmbH/Pratia city: Schwerin zip: 19055 country: Germany name: Julia Grindel role: CONTACT phone: +49 385 557 740 email: [email protected] name: Charlotte von Engelhardt role: PRINCIPAL_INVESTIGATOR lat: 53.62937 lon: 11.41316 hasResults: False
|
<|newrecord|> nctId: NCT06281223 id: JBR_2023_9 briefTitle: Study of Brain-spinal Cord Neural Connectivity in Spasticity acronym: MOVE overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2026-05 date: 2026-05 date: 2024-02-28 date: 2024-02-28 name: Fondation Ophtalmologique Adolphe de Rothschild class: NETWORK briefSummary: Little is known about the peripheral and central mechanisms of action of selective dorsal rhizotomy surgery for the treatment of spasticity. A better understanding of these mechanisms will enable us to improve the surgical procedure. This will require cortico-medullo-radiculo-muscular recordings never before performed and published in the literature, and the identification of variations in connectivity correlated with the clinic. conditions: Spasticity, Muscle studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 50 type: ESTIMATED name: intraoperative neuroelectrophysiological monitoring measure: variation in "spontaneous/resting" cortico-medullo-radiculo-muscular synchronization before and after selective rhizotomy surgery sex: ALL minimumAge: 3 Years maximumAge: 17 Years stdAges: CHILD hasResults: False
|
<|newrecord|> nctId: NCT06281210 id: IEO 2034 briefTitle: Vabb After Neoadjuvant Therapy to Avoid Surgery-pCR to Avoid Breast Surgery acronym: BETTY-CRASY overallStatus: RECRUITING date: 2023-12-11 date: 2028-12-31 date: 2028-12-31 date: 2024-02-28 date: 2024-02-28 name: European Institute of Oncology class: OTHER briefSummary: This single arm study aims to evaluate the efficacy and safety of a non-surgical approach, consisting of radiotherapy (RT) alone, for patients who have achieved a complete pathological response (pCR) following neoadjuvant chemotherapy (NACT). The study design involves the histological confirmation of pCR using vacuum-assisted biopsy (VABB) or vacuum-assisted excision (VAE) guided by ultrasound. The primary objective is to demonstrate that the non-surgical, RT-only treatment and follow-up approach is not inferior to the traditional surgical approach in patients with pCR after NACT. conditions: Breast Cancer conditions: Triple Negative Breast Cancer conditions: HER2-positive Breast Cancer conditions: Neoadjuvant Chemotherapy studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 77 type: ESTIMATED name: Omission of surgical treatment measure: Event-free survival measure: Positive predictive value of MRI measure: Contrast-Enhanced Mammography (CEM) positive predictive value sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Istituto di Candiolo IRCCS status: NOT_YET_RECRUITING city: Candiolo state: Turin zip: 10060 country: Italy name: Antonio Toesca, MD role: CONTACT lat: 44.95858 lon: 7.59812 facility: European Institute of Oncology status: RECRUITING city: Milan zip: 20141 country: Italy name: Elisabetta Rossi, MD role: CONTACT phone: +390294372191 email: [email protected] name: Mara Negri role: CONTACT email: [email protected] name: Elisabetta Rossi, MD role: PRINCIPAL_INVESTIGATOR lat: 45.46427 lon: 9.18951 hasResults: False
|
<|newrecord|> nctId: NCT06281197 id: 2021/48 briefTitle: Does Subspinal Le Fort I Osteotomy Affect the Nasal Airway Volume overallStatus: COMPLETED date: 2021-01-15 date: 2021-08-15 date: 2022-05-15 date: 2024-02-28 date: 2024-02-28 name: TC Erciyes University class: OTHER briefSummary: After the description of Le Fort fractures, maxillary osteotomies are used to correct dentofacial deformities. The profile changes on nasolabial region resulting from a Le Fort I osteotomy, also that affects nasal airway. The Subspinal Le Fort I osteotomy (SLFIO) describe to prevent undesirable soft tissue changes. In the literature, too many articles have reported the effectiveness of SLFIO in preventing nasal deformation. However, there is no study to evaluate the nasal volume or septum deviation. conditions: Maxillofacial Abnormalities studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: double blind primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: double blind whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 47 type: ACTUAL name: Conventional name: Subspinal measure: Evaluation of Septum Deviation measure: Evaluation of Nasal Airway measure: nasal obstruction scale evaluation sex: ALL minimumAge: 18 Years maximumAge: 40 Years stdAges: ADULT facility: Selin Çelebi city: Kayseri state: Meligazi zip: 38320 country: Turkey lat: 38.73222 lon: 35.48528 hasResults: False
|
<|newrecord|> nctId: NCT06281184 id: DIA2024.1 id: 715758 type: REGISTRY domain: Regional committee for medical and health research ethics briefTitle: A Post-trial Follow-up of MERINO Participants to Evaluate Long-term Effects of Methotrexate Treatment in Adults With Erosive Hand OA. acronym: MERINO:2 overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2027-02-01 date: 2027-02-01 date: 2024-02-28 date: 2024-02-28 name: Diakonhjemmet Hospital class: OTHER briefSummary: In response to the high prevalence of synovitis in hand osteoarthritis (OA) and its association with pain, there\&#39;s a compelling rationale for investigating the efficacy of MTX in managing inflammatory erosive hand OA. Recent guidelines highlight the need for large, well-designed trials to assess the effectiveness of MTX. A recent trial (METHODS study) showed promising pain reduction with MTX, but due to pandemic-related protocol changes, the duration of the study was limited to six months. The ongoing MERINO trial randomizes participants to MTX or placebo for one year. After completing the MERINO trial, several participants asked for MTX open label. In the subsequent MERINO:2 study, participants completing the trial will be invited to a structured follow-up after one year, including electronic questionnaires and hand radiographs, providing valuable long-term data on the effects of MTX in hand OA. Together, these trials aim to fill gaps in understanding the long-term impact of MTX in hand OA, particularly on structural progression. conditions: Hand Osteoarthritis conditions: Erosive Osteoarthritis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 108 type: ESTIMATED name: Methotrexate name: No treatment measure: Effect of MTX on radiographic progression of erosive hand OA. measure: Effect of MTX on pain, function and life quality measure: Effect of MTX on radiographic progression of hand OA. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Diakonhjemmet Hospital city: Oslo zip: 0319 country: Norway name: Ida Løchting role: CONTACT phone: +4722451500 email: [email protected] name: Alexander Mathiessen, MD PhD role: PRINCIPAL_INVESTIGATOR lat: 59.91273 lon: 10.74609 hasResults: False
|
<|newrecord|> nctId: NCT06281171 id: 90BISB0022 briefTitle: Evaluation of SkillTalk for Autistic Young Adults overallStatus: ACTIVE_NOT_RECRUITING date: 2024-03-01 date: 2024-07-31 date: 2024-08-31 date: 2024-02-28 date: 2024-04-17 name: dfusion Inc class: INDUSTRY briefSummary: The goal of this clinical trial is to evaluate the effectiveness of using a Microskills video training library for young adults, aged 18-28, with autism spectrum disorder (ASD) to enhance their skills in developing and maintaining healthy relationships.
|
The main questions it aims to answer are:
|
* Does using SkillTalk increase autistic young adults skills in the communications skills that are demonstrated in the video curriculum (skills: resolve conflict, compromise, give feedback)?
|
* Does using SkillTalk increase reported confidence and satisfaction in communication and relationship skills?
|
* Does using SkillTalk increase interpersonal competence?
|
* Does using SkillTalk increase ability to cope with rejection?
|
* Does using SkillTalk improve mental health and wellbeing?
|
Participants will be asked to:
|
* Take a survey at the beginning of the study, after one month the end of the study, and at 3-month follow up
|
* Participate in recorded video calls with projects staff, comprised of 2-3 brief roleplay scenarios of relationship skills at the beginning of the study, after one month the end of the study, and at 3-month follow up
|
* Watch a minimum of 85% of the 60 minutes of video assigned conditions: Autism Spectrum Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE count: 110 type: ESTIMATED name: SkillTalk for Autistic Young Adults name: Flyer Library measure: Demonstrated Skill Score in communication skills. measure: Participant Confidence & Satisfaction in their communication skills measure: Interpersonal Competence Score measure: Coping with Rejection, Jealousy and Relationship Anxiety measure: Mental Health and Wellbeing sex: ALL minimumAge: 18 Years maximumAge: 28 Years stdAges: ADULT facility: Virtual Study city: Santa Cruz state: California zip: 95060 country: United States lat: 36.97412 lon: -122.0308 hasResults: False
|
<|newrecord|> nctId: NCT06281158 id: DNLI-F-0009 briefTitle: A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants overallStatus: RECRUITING date: 2024-03 date: 2024-05 date: 2024-05 date: 2024-02-28 date: 2024-03-01 name: Denali Therapeutics Inc. class: INDUSTRY briefSummary: This is a Phase 1, open-label, nonrandomized, single-dose study in healthy male participants to investigate the absorption, metabolism and excretion of DNL343. conditions: Healthy Volunteers studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 7 type: ESTIMATED name: [14C]-DNL343 measure: PK Parameter: AUC0-∞ measure: PK Parameter: AUC0-tlast measure: PK Parameter: Cmax measure: PK Parameter: Tmax measure: PK Parameter: t1/2 measure: Total radioactivity in plasma and whole blood measure: Total radioactivity in blood-to-plasma ratio measure: Extent and rate of recovery of total radioactivity in urine and feces measure: PK Parameter: AUC0-∞ measure: PK Parameter: AUC0-tlast measure: PK Parameter: Cmax measure: PK Parameter: Tmax measure: PK Parameter: t1/2 measure: DNL343 and a DNL343 metabolite recoveries in urine measure: Incidence, severity, and seriousness of treatment-emergent adverse events (TEAEs) sex: MALE minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Clinical Site status: RECRUITING city: Madison state: Wisconsin zip: 53704 country: United States lat: 43.07305 lon: -89.40123 hasResults: False
|
<|newrecord|> nctId: NCT06281145 id: RSV-SK001/UC-SK004/OUSA briefTitle: Stress-Reducing Intervention in Patients With Colorectal and Breast Cancer acronym: SRI-BrCa_CRC overallStatus: RECRUITING date: 2024-03-15 date: 2027-03-15 date: 2029-03-15 date: 2024-02-28 date: 2024-02-28 name: Comenius University class: OTHER briefSummary: The goal of this interventional study is to test the heart-rate variability biofeedback intervention (HRV BI) in 2 cohorts of patients. Cohort A will evaluate the effect of the addition of HRV BI in patients with breast cancer treated in the neoadjuvant setting (vs. standard of care alone, SOC) followed by local therapy (surgery +/-radiotherapy). Cohort B will evaluate the effect of the addition of HRV BI in patients with colon cancer after surgery in the adjuvant setting (vs. standard of care alone, SOC). conditions: Breast Cancer conditions: Colon Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The study consists of two cohorts (breasts cancer and colorectal cancer) with two arms SOC + intervention vs SOC alone. primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 100 type: ESTIMATED name: Heart-rate variability biofeedback intervention measure: Primary endpoint - inflammation measure: Primary endpoint - QoL measure: Primary endpoint - executive functions measure: Primary endpoint- salivary cortisol slopes measure: Primary endpoint- sleep quality measure: Primary endpoint - heart rate variability (HRV) measure: Primary endpoint - Working memory measure: Secondary endpoint - Pathologic Complete Response (pCR) and Residual Cancer Burden (RCB) rate in cohort A measure: Secondary endpoint - Relapse-free Survival (RFS) measure: Secondary endpoint - Overall survival (OS) measure: Secondary endpoint - Serious Adverse Events (SAE) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: St. Elizabeth Cancer Institute status: RECRUITING city: Bratislava zip: 81250 country: Slovakia name: Bela Mrinakova, MD role: CONTACT phone: 00421232249111 email: [email protected] name: Miriam Hancinova, MD role: CONTACT phone: 00421232249111 email: [email protected] name: Bela Mrinakova role: PRINCIPAL_INVESTIGATOR name: Miriam Hancinova role: SUB_INVESTIGATOR lat: 48.14816 lon: 17.10674 hasResults: False
|
<|newrecord|> nctId: NCT06281132 id: A126_03BE2316 briefTitle: Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic After Oral Administration of CKD-341 and D956 in Healthy Adults overallStatus: ACTIVE_NOT_RECRUITING date: 2024-03-22 date: 2024-05-07 date: 2024-05-14 date: 2024-02-28 date: 2024-04-02 name: Chong Kun Dang Pharmaceutical class: INDUSTRY briefSummary: The objective was to evaluate and compare the pharmacokinetic profiles and safety after administration of test drug (CKD-341) and reference drugs (D956) in healthy adults. conditions: Hypertension studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: NONE count: 48 type: ACTUAL name: CKD-341, D956 measure: area under curve(AUC) of CKD-341, D956 measure: Cmax of CKD-341, D956 sex: ALL minimumAge: 19 Years maximumAge: 55 Years stdAges: ADULT facility: Jeonbuk National University Hospital city: Jeonju country: Korea, Republic of lat: 35.82194 lon: 127.14889 hasResults: False
|
<|newrecord|> nctId: NCT06281119 id: SII-qHPV/MC-03 briefTitle: Clinical Study to Evaluate SIIPL qHPV Vaccine (CERVAVAC®) in Women Living With HIV Aged 15-25 Years overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2025-12 date: 2026-05 date: 2024-02-28 date: 2024-02-28 name: Serum Institute of India Pvt. Ltd. class: INDUSTRY name: Bill and Melinda Gates Foundation briefSummary: Human papillomavirus (HPV) infection is the most common viral infection of the reproductive tract. Up to 80%of the sexually active females and men will be infected with HPV at some point in their lives and some may be repeatedly infected. The main burden of HPV-related disease is due to cervical cancer. Since cervical screening only detects precancerous and cancerous changes after they have occurred, HPV vaccination is primary prevention. People with HIV infection, even when effectively treated with antiretroviral therapy (ARV),are at higher risk of acquiring infection with multiple HPV types and are also known to be predisposed to a higher risk of HPV infection and subsequent CIN lesions. Vaccination of this high-risk group with HPV vaccine is highly beneficial. SIIPL's qHPV vaccine CERVAVAC®, India's first indigenous qHPV vaccine has received marketing authorization in India. The current study is a Phase 3b study to evaluate the immunogenicity and safety of two- and three-dose schedules of SIIPL qHPV vaccine in women living with HIV (WLWH) aged 15-25years. conditions: Human Papillomavirus Infection studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 450 type: ESTIMATED name: Cervavac as three dose regimen name: Cervavac as two dose regimen name: Gardasil as three dose regimen measure: Geometric mean titers of anti HPV 16 and 18 IgG antibodies measure: Immune response (Geometric mean titers) of anti HPV 6 and 11 IgG antibodies measure: Geometric mean titers of anti HPV 6, 11, 16 and 18 IgG antibodies and Pecentage seroconversion measure: Adverse Events measure: Geometric mean titers of anti HPV 6, 11, 16 and 18 IgG antibodies and Pecentage seroconversion measure: Geometric mean titers of anti HPV 6, 11, 16 and 18 IgG antibodies and Pecentage measure: CD4+ cell count, HIV viral load, and HIV clinical staging sex: FEMALE minimumAge: 15 Years maximumAge: 25 Years stdAges: CHILD stdAges: ADULT facility: Centre For Clinical Research, Kemri city: Nairobi zip: 54840-00200 country: Kenya name: Nelly Mugo role: CONTACT phone: +254733629665 email: [email protected] lat: -1.28333 lon: 36.81667 facility: Partners in Health and Research Development (Phrd) city: Thika zip: 19865-00202 country: Kenya name: Nelly Mugo role: CONTACT phone: +254733629665 email: [email protected] lat: -1.03326 lon: 37.06933 facility: Manhiça Health Research Center - Manhiça Foundation (CISM-FM) city: Manhiça zip: 1929 country: Mozambique name: Tacilta Nhampossa role: CONTACT phone: +258 21 810 181 email: [email protected] facility: Clinical HIV Research Unit (CHRU), Helen Joseph Hospital city: Johannesburg zip: 2092 country: South Africa name: Carla Chibwesha role: CONTACT phone: +27 072 744 7899 email: [email protected] lat: -26.20227 lon: 28.04363 hasResults: False
|
<|newrecord|> nctId: NCT06281106 id: IM011-1118 id: KOFAM 2023-01731 type: OTHER domain: CER-VD briefTitle: TYK2 Inhibition in Paradoxical Psoriasis acronym: TYPP overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-08 date: 2025-08 date: 2024-02-28 date: 2024-02-28 name: Prof Curdin Conrad class: OTHER name: Centre Hospitalier Universitaire Vaudois briefSummary: Paradoxical psoriasis is a side effect of a biological treatment (anti-tumor necrosis factor agent, short called anti-TNF) that is used to treat diseases of the skin, the intestine or the joints. If paradoxical psoriasis occurs, the anti-TNF-treatment often needs to be stopped and so far, no specific treatment for paradoxical psoriasis exists.
|
This research project aims to study whether the efficacy of the drug 'Deucravacitinib' 6mg, a tablet taken by mouth once a day is superior compared to taking a placebo in treating paradoxical psoriasis. conditions: Psoriasis studyType: INTERVENTIONAL phases: PHASE2 phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: During 4 weeks the patients of the 2 arms receive either Deucravacitinib 6mg 1x/day or an identically looking placebo.
|
At Week 4, Patients with underlying disease of Crohn's disease, colitis ulcerosa, uveitis will stop the study, to avoid that they are too long without efficient treatment for their underlying disease.
|
Patients with underlying disease of psoriasis or psoriatic arthritis will have the possiblity to continue in Part 2, where they all will receive Deucravacitinib 6mg 1x/day, open label for 3 months primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: Lab personnel whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 26 type: ESTIMATED name: Deucravacitinib measure: Paradoxical Psoriasis Investigator Global Assessment measure: Paradoxical Psoriasis Body Surface Area measure: Paradoxical Psoriasis palmoplantar Psoriasis Area and Severity Index measure: Paradoxical Psoriasis Scalp Investigator General Assessment measure: Psoriasis Area and Severity Index (PASI) measure: American College of Rheumatology (ACR) Score measure: Nanostring sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Centre hospitalier universitaire vaudois (CHUV) city: Lausanne state: VD zip: 1011 country: Switzerland name: Franziska Stuber, RN role: CONTACT phone: +41 21 3143427 email: [email protected] name: Curdin Conrad, Professor role: PRINCIPAL_INVESTIGATOR lat: 46.516 lon: 6.63282 hasResults: False
|
<|newrecord|> nctId: NCT06281093 id: PI2022_843_0089 briefTitle: Radiofrequency Fields in Neonatology: Exposure and Impact on the Nervous System acronym: CHARLINE overallStatus: RECRUITING date: 2024-02-20 date: 2026-09 date: 2026-10 date: 2024-02-28 date: 2024-03-13 name: Centre Hospitalier Universitaire, Amiens class: OTHER name: University Hospital, Brest name: CHU LYON name: University Hospital, Strasbourg, France name: University Hospital, Toulouse briefSummary: Previously, the investigators showed that preterm newborns are exposed chronically to very low radiofrequency levels in average while hospitalized in NICUs. Most of the infants were nevertheless frequently exposed to transient values above 1 V/m. The investigators also showed that an increase in RF exposure is likely to alter the activity of some neurophysiological functions and their regulatory systems in preterm newborns. The investigators hypothesize that above results are extremely specific to the location of the previous study and may be different in other NICU environments.
|
This study will aim at quantifying RF levels to which preterm newborns are exposed during their stay in several NICUs spread across the French territory, and assessing its impact on the central and peripheral nervous systems. The first step of this study will be to quantify the precise, continuous and individual levels of daily RF exposure to which each recruited neonate is subjected during his stay in the different NICUs from birth to 1 week postnatal life. Infants' clinical data (medical history, nutrition, morphology...) will also be continually monitored. At 1 week postnatal life, the investigators will investigate cerebral activity (EEG) and autonomic nervous system activity (ECG, heart rate variability). The impact of RF will be evaluated by analyses of the relationship between exposure levels and the various parameters extracted from the neurophysiological investigation phase. conditions: Preterm Newborn studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: BASIC_SCIENCE masking: NONE count: 200 type: ESTIMATED name: questionary name: Daily continuous recording of radiofrequency exposure levels name: Follow-up of daily infants clinical parameters name: recording of cerebral (EEG) name: autonomic nervous (ECG) activity measure: Variation of the spectral power in the α band (8-12 Hz) of the EEG measure: variation of the spectral power in the delta (δ, 0.5-4 Hz) of the EEG sex: ALL minimumAge: 1 Day maximumAge: 1 Month stdAges: CHILD facility: Amiens University Hospital status: RECRUITING city: Amiens state: Picardie zip: 80054 country: France name: Pierre Tourneux, MD role: CONTACT phone: +33 3 22 66 82 86 email: [email protected] name: Erwan STÉPHAN-BLANCHARD, Dr role: PRINCIPAL_INVESTIGATOR name: Stéphane DELANAUD, PhD role: SUB_INVESTIGATOR name: Frédéric TELLIEZ, Pr role: SUB_INVESTIGATOR name: Karen CHARDON, Pr role: SUB_INVESTIGATOR name: Brahim SELMAOUI, Dr role: SUB_INVESTIGATOR name: Débora TUKA role: SUB_INVESTIGATOR name: Jean-Michel ROUÉ, Pr role: PRINCIPAL_INVESTIGATOR name: Marine BUTIN, Pr role: PRINCIPAL_INVESTIGATOR name: Pierre KUHN, Pr role: PRINCIPAL_INVESTIGATOR name: Géraldine GASCOIN, Pr role: PRINCIPAL_INVESTIGATOR lat: 49.9 lon: 2.3 hasResults: False
|
<|newrecord|> nctId: NCT06281080 id: CRE2023.589-T briefTitle: First-in-Human Trial of a Novel Endoluminal Robotic System for En-Bloc Resection of Bladder Tumours overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2025-06-30 date: 2025-09-30 date: 2024-02-28 date: 2024-02-28 name: Chinese University of Hong Kong class: OTHER name: Agilis Robotics Limited briefSummary: This is a prospective, single-arm study to evaluate the feasibility and safety of performing transurethral en-bloc resection of bladder tumours using the Zenith robotic system. conditions: Bladder Cancer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: En-Bloc Resection of Bladder Tumours measure: Successful en-bloc tumour resection by the robotic system measure: Dissection time and speed measure: Total procedure time measure: Surgeon Console time measure: Presence of detrusor muscle in specimen measure: Resection Margin measure: Intra-operative bladder perforation event measure: Post-operative complications measure: Need of bladder irrigation measure: Residual tumour or upstaging of tumour after second look TURBT sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06281067 id: 271.673 briefTitle: Reassessment of myocardIAL Bridge TOwards PeRsOnalized Medicine acronym: RIALTO PRO overallStatus: RECRUITING date: 2023-12-15 date: 2026-01-01 date: 2026-01-01 date: 2024-02-28 date: 2024-02-28 name: Azienda Ospedaliero Universitaria Maggiore della Carita class: OTHER name: Università degli Studi del Piemonte Orientale "Amedeo Avogadro" briefSummary: The "RIALTO-PRO" study aims to optimize the diagnostic and therapeutic algorithm for myocardial bridge (MB) patients, testing the diagnostic value of a full invasive diagnostic procedure, and, consequently, the prognostic value of a tailored approach. the study objective is to determine the diagnostic and prognostic value of a full-physiology approach strategy versus a standard approach strategy in patients with a MB.
|
The "RIALTO PRO" study is a randomized, multicentre, prospective, open-label, superiority trial comparing a personalised versus standard management in patients with MB. Consenting and eligible patients will be randomised 1:1 to either a "full-physiology approach", consisting of a comprehensive diagnostic algorithm aimed at unmasking the main pathophysiological mechanism of myocardial ischemia and consequently a tailored treatment, or a "standard approach", consisting of angiographic evaluation of the tunnelled segment. conditions: Myocardial Bridge studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: DIAGNOSTIC masking: NONE count: 500 type: ESTIMATED name: "full-physiology approach" arm name: "standard approach" arm measure: The composite of significant angina and MACE measure: Rate of patients with significant angina (SAQ Angina Summary Score ≤ 70) measure: Incidence of MACE measure: Rate of cardiac death measure: Rate of MI measure: Rate of cardiac hospitalization measure: Rate of TLR sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ospedale Generale Regionale F. Miulli status: NOT_YET_RECRUITING city: Acquaviva Delle Fonti country: Italy lat: 40.89704 lon: 16.8433 facility: Azienda Ospedaliera Nazionale Santi Antonio e Biagio e Cesare Arrigo status: NOT_YET_RECRUITING city: Alessandria country: Italy lat: 44.90924 lon: 8.61007 facility: Ospedale San Donato status: NOT_YET_RECRUITING city: Arezzo country: Italy lat: 43.46276 lon: 11.88068 facility: ASST Papa Giovanni XXIII status: NOT_YET_RECRUITING city: Bergamo country: Italy lat: 45.69601 lon: 9.66721 facility: Ospedale degli Infermi di Biella status: NOT_YET_RECRUITING city: Biella country: Italy lat: 45.56304 lon: 8.05796 facility: Policlinico S. Orsola IRCCS Azienda Ospedaliero Universitaria status: NOT_YET_RECRUITING city: Bologna country: Italy lat: 44.49381 lon: 11.33875 facility: Azienda Ospedaliera di Rilievo Nazionale Sant'Anna e San Sebastiano status: NOT_YET_RECRUITING city: Caserta country: Italy lat: 41.07262 lon: 14.33231 facility: Villa Maria Cecilia Hospital status: NOT_YET_RECRUITING city: Cotignola country: Italy lat: 44.38572 lon: 11.93852 facility: Azienda Ospedaliero Universitaria di Ferrara status: NOT_YET_RECRUITING city: Ferrara country: Italy lat: 44.83804 lon: 11.62057 facility: Azienda Ospedaliero Universitaria Careggi status: NOT_YET_RECRUITING city: Firenze country: Italy lat: 43.77925 lon: 11.24626 facility: Azienda Ospedaliera Universitaria Policlinico San Martino status: NOT_YET_RECRUITING city: Genova country: Italy lat: 44.40478 lon: 8.94438 facility: Ospedale Della Misericordia status: NOT_YET_RECRUITING city: Grosseto country: Italy lat: 42.76296 lon: 11.10941 facility: Centro Cardiologico Monzino IRCCS status: NOT_YET_RECRUITING city: Milano country: Italy lat: 45.46427 lon: 9.18951 facility: IRCCS Ospedale Galeazzi status: NOT_YET_RECRUITING city: Milano country: Italy lat: 45.46427 lon: 9.18951 facility: Fondazione IRCCS San Gerardo dei Tintori status: NOT_YET_RECRUITING city: Monza country: Italy lat: 45.58005 lon: 9.27246 facility: AOU Maggiore della Carità status: RECRUITING city: Novara zip: 28100 country: Italy name: Domenico D'Amario, Prof role: CONTACT phone: 0039 0321 3733141 email: [email protected] name: Domenico D'Amario, Prof role: PRINCIPAL_INVESTIGATOR name: Giuseppe Patti, Prof role: PRINCIPAL_INVESTIGATOR lat: 45.44694 lon: 8.62118 facility: Azienda Ospedaliero Universitaria di Parma status: NOT_YET_RECRUITING city: Parma country: Italy lat: 44.79935 lon: 10.32618 facility: Azienda Ospedaliera di Perugia status: NOT_YET_RECRUITING city: Perugia country: Italy lat: 43.1122 lon: 12.38878 facility: Azienda Ospedaliero Universitaria Pisana status: NOT_YET_RECRUITING city: Pisa country: Italy lat: 43.70853 lon: 10.4036 facility: Ospedale San Jacopo status: NOT_YET_RECRUITING city: Pistoia country: Italy lat: 43.93064 lon: 10.92365 facility: Ospedali Riuniti di Rivoli status: NOT_YET_RECRUITING city: Rivoli country: Italy lat: 45.07073 lon: 7.51465 facility: Aurelia Hospital status: NOT_YET_RECRUITING city: Roma country: Italy lat: 41.89193 lon: 12.51133 facility: Azienda Ospedaliera San Camillo-Forlanini status: NOT_YET_RECRUITING city: Roma country: Italy lat: 41.89193 lon: 12.51133 facility: Azienda Ospedaliero Universitaria Sant'Andrea status: NOT_YET_RECRUITING city: Roma country: Italy lat: 41.89193 lon: 12.51133 facility: Fondazione Policlinico Universitario Agostino Gemelli IRCCS status: RECRUITING city: Roma country: Italy lat: 41.89193 lon: 12.51133 facility: Ospedale Sandro Pertini status: NOT_YET_RECRUITING city: Roma country: Italy lat: 41.89193 lon: 12.51133 facility: Ospedale Santo Spirito status: NOT_YET_RECRUITING city: Roma country: Italy lat: 41.89193 lon: 12.51133 facility: Policlinico Universitario Tor Vergata Fondazione PTV status: NOT_YET_RECRUITING city: Roma country: Italy lat: 41.89193 lon: 12.51133 facility: Ospedale Civile Santissima Annunziata status: NOT_YET_RECRUITING city: Sassari country: Italy lat: 40.72586 lon: 8.55552 facility: Azienda Sanitaria Provinciale di Siracusa status: NOT_YET_RECRUITING city: Siracusa country: Italy lat: 37.08415 lon: 15.27628 facility: Azienda Ospedaliera Ordine Mauriziano status: NOT_YET_RECRUITING city: Torino country: Italy lat: 45.07049 lon: 7.68682 facility: Azienda Ospedaliero Universitaria Città Della Salute E Scienza status: NOT_YET_RECRUITING city: Torino country: Italy lat: 45.07049 lon: 7.68682 facility: Presidio Ospedaliero Sant'Andrea status: NOT_YET_RECRUITING city: Vercelli country: Italy lat: 45.32163 lon: 8.41989 facility: Azienda Ospedaliera Universitaria Integrata, Ospedale Borgo Trento status: NOT_YET_RECRUITING city: Verona country: Italy lat: 45.4299 lon: 10.98444 hasResults: False
|
<|newrecord|> nctId: NCT06281054 id: SMC2023-12-027 briefTitle: Acute Myocardial Infarction in Cancer Patients overallStatus: ACTIVE_NOT_RECRUITING date: 2002-01-01 date: 2021-12-31 date: 2024-12-31 date: 2024-02-28 date: 2024-02-28 name: Samsung Medical Center class: OTHER name: Chonnam National University briefSummary: Using national health insurance service database, current study aim to evaluate the risk and prognosis of acute myocardial infarction in cancer patients and to find the optimal treatment strategy for acute myocardial infarction that can improve long-term prognosis. conditions: Acute Myocardial Infarction conditions: Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 4500000 type: ESTIMATED name: Revascularization measure: All-cause death measure: Myocardial infarction measure: Revascularization measure: Hospitalization for heart failure measure: Stroke measure: Clinically relevant bleeding sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Chonnam National University Hospital, Chonnam National University Medical School city: Gwangju country: Korea, Republic of lat: 35.15472 lon: 126.91556 hasResults: False
|
<|newrecord|> nctId: NCT06281041 id: NHIS20240220 briefTitle: Nationwide Cohort Study of Antiplatelet Agents as Primary Prevention acronym: NHIS overallStatus: ACTIVE_NOT_RECRUITING date: 2013-01-01 date: 2020-12-31 date: 2024-12-31 date: 2024-02-28 date: 2024-02-28 name: Samsung Medical Center class: OTHER name: Chonnam National University briefSummary: There is no specific recommendation regarding pharmacologic treatment as primary prevention for patients with intermediate coronary artery stenosis whose revascularization was deferred based on negative fractional flow reserve (FFR).
|
Current nationwide cohort study conducted using Korean National Health Insurance Service database evaluated the safety and efficacy of antiplatelet therapy in patients with intermediate coronary artery stenosis with deferred revascularization based on negative FFR (FFR\>0.80). conditions: Coronary Artery Disease conditions: Coronary Artery Stenosis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 4657 type: ACTUAL name: Antiplatelet Agents measure: Major adverse cardiac and cerebrovascular events measure: Gastrointestinal bleeding measure: All-cause death measure: Myocardial infarction measure: Unplanned revascularization measure: Stroke measure: Major bleeding measure: Gastrointestinal bleeding necessitated hospitalization without documented transfusion measure: Intracranial hemorrhage sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Chonnam National University Medical School city: Gwangju country: Korea, Republic of lat: 35.15472 lon: 126.91556 hasResults: False
|
<|newrecord|> nctId: NCT06281028 id: 2023-A02280-45 briefTitle: SOLACEA-H in Heparin-sparing Haemodialysis acronym: SOLHEPA overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2025-09 date: 2025-09 date: 2024-02-28 date: 2024-02-28 name: GCS Ramsay Santé pour l'Enseignement et la Recherche class: OTHER briefSummary: The aim of the study is to evaluate the efficacy of the SOLACEA-H dialyser, particularly in patients at high risk of haemorrhage, during post-dilution haemodiafiltration sessions with complete or partial heparin sparing. It will be compared with another dialyser (HYDROLINK-NVU) conditions: Dialysis Membrane Reaction studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Prospective, multicenter, randomized primaryPurpose: TREATMENT masking: NONE count: 19 type: ESTIMATED name: SOLACEA-H/HYDROLINK-NVU name: HYDROLINK-NVU/SOLACEA-H measure: SOLACEA-H vs HYDROLINK-NVU efficacy sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hôpital Privé La Louvière city: Lille zip: 59800 country: France name: Maxime HOFFMANN, MD role: CONTACT phone: 6 86 70 91 23 phoneExt: +33 email: [email protected] lat: 50.63297 lon: 3.05858 hasResults: False
|
<|newrecord|> nctId: NCT06281015 id: 2023PI095-407 briefTitle: Artificial Intelligence and Bone Tomoscintigraphies Achieved With CZT Camera acronym: IATOS overallStatus: COMPLETED date: 2023-08-30 date: 2023-09-10 date: 2023-10-30 date: 2024-02-28 date: 2024-02-28 name: Central Hospital, Nancy, France class: OTHER briefSummary: This study aimed to determine whether the whole-body bone Single Photon Emission Computed Tomography (SPECT) recording times of around 10 minutes, routinely provided by a high-sensitivity 360 degrees cadmium and zinc telluride (CZT) camera, can be further reduced by a deep learning noise reduction (DLNR) algorithm. conditions: Bone Lesion studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: RETROSPECTIVE count: 19 type: ACTUAL name: Whole-body bone single photon emission tomography (SPECT) for detection or follow-up of bone metastasis measure: Assess a dedicated deep learning noise reduction algorithm sex: ALL minimumAge: 18 Years maximumAge: 95 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CHRU Nancy city: Vandoeuvre les Nancy cedex zip: 54511 country: France lat: 48.65 lon: 6.18333 hasResults: False
|
<|newrecord|> nctId: NCT06281002 id: FDASU-RecIM112323 briefTitle: Trueness of Full Arch Scans and Generated Digital Implant Models overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-10 date: 2024-12 date: 2024-02-28 date: 2024-03-06 name: Ain Shams University class: OTHER briefSummary: The goal of this clinical trial study is to evaluate the accuracy of the full digital workflow for four-implant, screw-retained mandibular hybrid prostheses in patients with completely edentulous mandible. conditions: Denture conditions: Complete Edentulism studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 9 type: ESTIMATED name: conventional impression stone casts digitization name: digital scanning with coupled scanning aiding device name: Digital Implant Model assessment of accuracy measure: Trueness of full arch digital scans when additional geometric scanning aids are coupled with the scan bodies. measure: Trueness of the generated 3D-printed digital implant models. sex: ALL minimumAge: 45 Years maximumAge: 60 Years stdAges: ADULT hasResults: False
|
<|newrecord|> nctId: NCT06280989 id: P.T.REC/012/004768 briefTitle: Effect of Kinesio Taping Versus Myofascial Release on Menstrual Low Back Pain overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2024-07 date: 2024-08 date: 2024-02-28 date: 2024-02-29 name: Cairo University class: OTHER briefSummary: the aim of this study is to investigate the efficacy of kinesio taping versus myofascial release technique on menstrual low back pain in young females conditions: Low Back Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: kinesio taping and myofascial release technique primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 44 type: ESTIMATED name: kinesio taping name: myofascial release technique measure: pain intensity measure: pain pressure threshold measure: severity of dysmenorrhea measure: Assess the function disability level sex: FEMALE minimumAge: 18 Years maximumAge: 25 Years stdAges: ADULT facility: Hala mohamed ahmed morsy city: Giza zip: 12511 country: Egypt name: hala ma morsy, Bachelor role: CONTACT phone: 00201028616865 email: [email protected] lat: 30.00808 lon: 31.21093 hasResults: False
|
<|newrecord|> nctId: NCT06280976 id: 23.0001 briefTitle: Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP) acronym: ARTCAP overallStatus: RECRUITING date: 2024-03-01 date: 2029-01-31 date: 2029-01-31 date: 2024-02-28 date: 2024-04-25 name: University of Louisville class: OTHER briefSummary: The purpose of this study is to evaluate the role of coronary CT angiogram (CCTA) as a superior guide for the assessment of coronary artery plaque and guiding treatment decisions. The investigators also assess the impact of preventive cardiovascular drugs on the plaque to improve patient outcomes. Participants aged 18-80 years, at intermediate or high-risk for coronary artery disease, with non-obstructive plaque on initial CCTA, will be enrolled in this study. They will be randomized into Standard of Care (SOC) vs. Aggressive Therapy (AT) groups. Both groups will undergo dietary and lifestyle interventions. Follow-up will consist of blood tests and clinic visits at baseline, 9 months, and 18 months. The second CCTA will be performed at 18 months to assess the change in plaque burden, characteristics, ischemia and pericoronary/epicardial fat. conditions: Coronary Artery Disease conditions: Atherosclerosis conditions: Heart Attack studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: PROBE design: Prospective Randomized Open Label Blinded End-point primaryPurpose: TREATMENT masking: NONE count: 200 type: ESTIMATED name: Statin name: Aspirin tablet name: Nexlizet name: LEQVIO name: Vascepa name: Jardiance name: Colchicine measure: Plaque quantification measure: Characterization of plaque to evaluate for high-risk features - positive remodeling measure: Quantification of stenosis measure: Quantification of pericoronary fat attenuation. measure: Characterization of plaque to evaluate for high-risk features - low CT attenuation measure: Characterization of plaque to evaluate for high-risk features - napkin-ring sign measure: Quantification of epicardial fat attenuation. measure: Major adverse cardiac and cardiovascular events (MACCE) measure: Polygenic risk score (PRS) measure: Next generation sequencing (NGS) measure: Change in Lipoprotein (a) measure: Change in myeloperoxidase (MPO) activity measure: Change in trimethylamine-N-oxide (TMAO) levels measure: Change in lipoprotein-associated phospholipase A2 (Lp-PLA2) levels measure: Change in interleukin-6 (IL-6) levels measure: Change in high sensitivity C-creative protein (HS-CRP) levels measure: Buffy coat for chromatin immunoprecipitation (ChIP) measure: Change in high sensitivity Troponin (HS-Tn) measure: Change in natriuretic peptide (BNP, NT-pro BNP measure: Change in levels of open reading frame 1 protein (ORF1p) sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Louisville School of Medicine, Division of Cardiovascular Diseases status: RECRUITING city: Louisville state: Kentucky zip: 40202 country: United States name: Dinesh Kalra, MD role: CONTACT phone: 502-588-7010 email: [email protected] name: Muhammad Umer, MD role: CONTACT phone: 502-588-7010 email: [email protected] lat: 38.25424 lon: -85.75941 hasResults: False
|
<|newrecord|> nctId: NCT06280963 id: 012/005532 briefTitle: Posterior Innominate Mobilization Versus Muscle Energy Technique on Lumbopelvic Angles in Sacroiliac Joint Dysfunction acronym: MET overallStatus: RECRUITING date: 2024-02-01 date: 2024-06-01 date: 2024-08-03 date: 2024-02-28 date: 2024-02-28 name: Mahmoud Yousry Rashwan Hefny class: OTHER briefSummary: the goal of this clinical trial study is to compare between posterior innominate mobilization and muscle energy techniqueon lumbopelvic angles in sacroiliac joint dysfunction patients.
|
the main questions they aim to answer are
|
1. are there statistical significant effects of posterior innominate mobilization versus muscle energy technique on lumbopelvic angles in sacroiliac joint dysfunction patients ?
|
2. are there statistical significant effects of posterior innominate mobilization versus muscle energy technique on pain intensity level in sacroiliac joint dysfunction patients ?
|
* purpose of the study is to measure the effect of muscle energy technique versus posterior innominate mobilization on lumbopelvic angles in sacroiliac joint dysfunction conditions: Sacroiliac Joint Dysfunction studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: FACTORIAL interventionModelDescription: group one will receive muscle energy technique group two will receive posterior innominate mobilization group three will receive conventional treatment ( TENS , US , stertching exercises and strenghening exercises ) primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 60 type: ESTIMATED name: muscle energy technique name: posterior innominate mobilization name: conventional treatment measure: lumbopelvic angles measure: pain intensity sex: ALL minimumAge: 25 Years maximumAge: 45 Years stdAges: ADULT facility: Faculty of Physical Therapy status: RECRUITING city: Dokki state: Giza zip: 12612 country: Egypt name: Haytham M Elhafez, PhD role: CONTACT phone: +201001909630 email: [email protected] lat: 30.03823 lon: 31.2113 hasResults: False
|
<|newrecord|> nctId: NCT06280950 id: DAIT CTOT-43 briefTitle: Expanding Liver Transplant Immunosuppression Minimization Via Everolimus acronym: ELIMINATE overallStatus: NOT_YET_RECRUITING date: 2024-03-31 date: 2027-06-01 date: 2029-06-01 date: 2024-02-28 date: 2024-02-28 name: National Institute of Allergy and Infectious Diseases (NIAID) class: NIH briefSummary: This is a study to determine the safety, efficacy, and tolerability of taking away the anti-rejection medicine, tacrolimus, in liver transplant recipients in conjunction with everolimus monotherapy to preserve renal function. Two hundred - seventy (270) subjects will be randomized 2:1 into one of two groups between 2-3 months post-transplant. Seventy participants will be placed into an observational group and will remain on their current post-transplant medications. The duration of the study from time of enrollment is 18-20 months. conditions: Liver Transplant studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 340 type: ESTIMATED name: Everolimus name: Tacrolimus (continued reduction) name: Tacrolimus (maintain 50% reduction) name: Everolimus measure: Percent change in estimated glomerular filtration rate (eGFR) by CKD-EPI 2021 equation. Between Cohorts INT-1 and INT-2 measure: Proportion of subjects with treated Biopsy Proven Acute Rejection (tBPAR) per local pathology. Between cohorts INT-1 and INT-2 measure: Percent change in Estimated Glomerular Filtration Rate (eGFR) in Renal function measure: Percentage of subjects with treated Biopsy Proven Acute Rejection (tBPAR) in Liver Function measure: Changes in liver graft function: Total bilirubin measure: Changes in liver graft function: Direct bilirubin measure: Changes in liver graft function: Alanine Aminotransaminase (ALT) measure: Changes in liver graft function: Aspartate Aminotransferase (AST) measure: Changes in liver graft function: Alkaline Phosphatase measure: Time to graft failure in liver function defined as relisting for transplantation, re-transplantation itself or death with failed graft measure: Time to all-cause mortality measure: Proportion of subjects experiencing a Major Adverse Cardiac Event (MACE) measure: Proportion of subjects experiencing infection requiring hospitalization measure: Proportion of subjects experiencing any malignancy measure: Proportion of subjects developing severe Estimated Glomerular Filtration Rate (eGFR) deterioration >40 percent from baseline using the CKD-EPI 2021 equation measure: Proportion of subjects developing any major immunosuppressive therapy complications measure: Proportion of subjects developing new onset peripheral edema measure: Proportion of subjects developing new onset cytopenia deemed WBC <3.0x10^9 /L, Hb <8.0 g/dL, or platelets <50 x 10^9/L. measure: Proportion of subjects developing new onset oral/gastrointestinal ulcerations measure: Proportion of subjects developing new onset gastrointestinal symptoms (nausea, vomiting, abdominal pain, or diarrhea) related to everolimus therapy. measure: Proportion of subjects developing new onset pneumonitis measure: Proportion of subjects developing new onset hepatic artery thrombosis measure: Proportion of subjects developing other adverse events deemed measure: Proportion of subjects developing any adverse events related to everolimus therapy sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic Hospital Arizona (Site #: 71144) city: Phoenix state: Arizona zip: 85054 country: United States name: Hugo Vargas, MD role: PRINCIPAL_INVESTIGATOR lat: 33.44838 lon: -112.07404 facility: University of California, San Francisco (Site #: 71108) city: San Francisco state: California zip: 94143 country: United States name: Joanna Kwan role: CONTACT phone: 415-476-2574 email: [email protected] name: Sandy Feng, MD role: PRINCIPAL_INVESTIGATOR lat: 37.77493 lon: -122.41942 facility: Northwestern University (Site #: 71110) city: Chicago state: Illinois zip: 60611 country: United States name: Dania Jahangir role: CONTACT email: [email protected] name: Justin Boike, MD role: PRINCIPAL_INVESTIGATOR lat: 41.85003 lon: -87.65005 facility: Icahn School of Medicine at Mount Sinai (Site #: 71115) city: New York state: New York zip: 10029 country: United States name: Bharathi Ramesh role: CONTACT email: [email protected] name: Thomas Schiano, MD role: PRINCIPAL_INVESTIGATOR lat: 40.71427 lon: -74.00597 facility: Duke University Medical Center (Site #: 71139) city: Durham state: North Carolina zip: 27710 country: United States name: Linda Perry role: CONTACT email: [email protected] name: Carl Berg, MD role: PRINCIPAL_INVESTIGATOR lat: 35.99403 lon: -78.89862 facility: University of Pennsylvania (Site #: 71111) city: Philadelphia state: Pennsylvania zip: 19104 country: United States name: Lexi Tumblety role: CONTACT phone: 267-441-1800 email: [email protected] name: Abraham Shaked, MD role: PRINCIPAL_INVESTIGATOR lat: 39.95233 lon: -75.16379 facility: University of Pittsburgh Medical Center (Site #: 71162) city: Pittsburgh state: Pennsylvania zip: 15260 country: United States name: Lois Kipling role: CONTACT email: [email protected] name: Scott Biggins, MD role: PRINCIPAL_INVESTIGATOR lat: 40.44062 lon: -79.99589 facility: Baylor Medical Center (Site #: 71153) city: Dallas state: Texas zip: 75246 country: United States name: Angela Roy role: CONTACT email: [email protected] name: Sumeet Asrani, MD role: PRINCIPAL_INVESTIGATOR lat: 32.78306 lon: -96.80667 hasResults: False
|
<|newrecord|> nctId: NCT06280937 id: BEUFTR-2 briefTitle: Short Term Effect of Wearing a Tie overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2024-08-01 date: 2024-10-01 date: 2024-02-28 date: 2024-02-28 name: Bitlis Eren University class: OTHER briefSummary: The goal of this randomized controlled study is to assess the short term effect of wearing a ties on musculoskeletal system. In this scope viscoelastic properties and the mechanosensitivity of the muscles, and cervical range of motion will be measured. In addition to these measurements activity limitation due to wearing a tie and trunk mobility will be assessed. conditions: Musculoskeletal Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Control group will go on their routine daily activities. Study group will wear a tie during one office working day. primaryPurpose: PREVENTION masking: SINGLE maskingDescription: Interventions and assessment will be performed by separate researchers. whoMasked: OUTCOMES_ASSESSOR count: 54 type: ESTIMATED name: Wearing a tie measure: The Change in the Viscoelastic Properties of the Muscles measure: The Change in the Pressure Pain Threshold of the Spine and Upper Trapezius measure: Cervical Range of Motion measure: Activity Limitation measure: Global Rating of Change measure: Trunk Forward Bending Mobility measure: Trunk Lateral Bending Mobility measure: Neck Circumference sex: MALE minimumAge: 18 Years maximumAge: 25 Years stdAges: ADULT facility: Bitlis Eren University city: Bitlis state: Merkez zip: 13000 country: Turkey lat: 38.40115 lon: 42.10784 hasResults: False
|
<|newrecord|> nctId: NCT06280924 id: HREBA.CC-23-0220 briefTitle: Prehab Prior to Stem Cell Transplantation in Multiple Myeloma acronym: MOTIVATE overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2025-12-31 date: 2026-06-30 date: 2024-02-28 date: 2024-02-28 name: University of Alberta class: OTHER briefSummary: The primary purpose of this study is to see if individuals with Multiple Myeloma are able and interested in taking part in a tailored exercise program while undergoing their chemotherapy prior to a stem cell transplant. We also hope to learn if this type of program, along with a flexible delivery format (in-person and virtual), helps in maintaining or improving physical fitness, muscle mass and strength, and quality of life during chemotherapy. conditions: Multiple Myeloma conditions: Exercise conditions: Prehabilitation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized controlled trial primaryPurpose: SUPPORTIVE_CARE masking: SINGLE maskingDescription: An independent assessor will conduct the post-intervention assessment. The independent assessor will be blinded to group assignment. whoMasked: OUTCOMES_ASSESSOR count: 30 type: ESTIMATED name: Supported Exercise name: Standard Care measure: Study completion rate measure: Recruitment rate measure: Attendance rate measure: Edmonton Symptom Assessment System measure: Functional Assessment of Cancer Therapy Multiple Myeloma measure: Functional Assessment of Cancer Therapy: Fatigue Subscale (13-item) measure: Body weight measure: Body height measure: Grip Strength measure: Calf muscle size measure: Thigh muscle thickness measure: Short Physical Performance Battery measure: Six-minute walk test measure: One leg stance balance measure: Shoulder flexion range of motion measure: Sit and reach test sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Alberta/ Cross Cancer Institute city: Edmonton state: Alberta zip: T6G 2G4 country: Canada lat: 53.55014 lon: -113.46871 hasResults: False
|
<|newrecord|> nctId: NCT06280911 id: 098 briefTitle: The Effect of Consumption of Date Fruit and Nipple Stimulation in Late Pregnancy overallStatus: COMPLETED date: 2013-10-10 date: 2014-06-30 date: 2017-12-30 date: 2024-02-28 date: 2024-03-04 name: Selcuk University class: OTHER briefSummary: The study was conducted to determine the effect of consumption of date fruit and nipple stimulation on labor.
|
The samples were applied to pregnant women satisfying the research criteria in a state hospital in Istanbul between October 2013 and June 2014. conditions: Augmentation conditions: Induction conditions: Labor conditions: Stimulation, Self studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The study was designed to be randomly controlled. primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 198 type: ACTUAL name: Date Fruit group name: Nipple group measure: The spontaneous onset of labor measure: Induction and augmentation of labor measure: Mode of delivery sex: FEMALE minimumAge: 18 Years maximumAge: 35 Years stdAges: ADULT facility: Zeynep Kamil Women's and Children's Diseases Training and Research Hospital city: Istanbul country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
|
<|newrecord|> nctId: NCT06280898 id: KC22RISI0395 briefTitle: Perioperative Factors and Early Postoperative Kidney Graft Function Recovery overallStatus: COMPLETED date: 2020-05-01 date: 2022-03-14 date: 2022-03-14 date: 2024-02-28 date: 2024-02-29 name: Seoul St. Mary's Hospital class: OTHER briefSummary: Divided into two groups based on acute kidney injury: non-acute kidney injury group vs. non-acute kidney injury group. Acute kidney injury group, Acute Kidney Injury Network (AKIN), Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease (RIFLE), or Kidney Disease: Improving Global Outcomes (KDIGO) I would like to divide it according to the definition. After testing the normal distribution of patients, donors, grafts, types of immunosuppressants, surgery/anesthesia factors, and blood test findings between the two groups through the Shapiro-Wilk test, continuous data was tested using the student t-test or Mann-Whitney U test. Sizes are compared using , and categorical data is compared with proportions using the χ2 test or Fisher's exact test. Analysis of factors related to acute kidney injury will be performed through univariate and multivariate logistic regression analysis. conditions: Heart Injuries conditions: Kidney Transplant; Complications studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 539 type: ACTUAL name: Remote ischemic conditioning measure: Troponin I measure: Troponin T measure: QTc interval sex: ALL minimumAge: 19 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Seoul St. Mary's hospital city: Seoul zip: 06591 country: Korea, Republic of lat: 37.566 lon: 126.9784 hasResults: False
|
<|newrecord|> nctId: NCT06280885 id: FIERCE briefTitle: A Flexible Individualized ExeRcise Programme for Cancer Patients During ChEmotherapy acronym: FIERCE overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2025-09-01 date: 2026-03-31 date: 2024-02-28 date: 2024-02-28 name: University of Dublin, Trinity College class: OTHER name: St. James's Hospital, Ireland briefSummary: The primary aim of this study is to measure the feasibility of delivering a co-designed exercise programme for patients with cancer receiving chemotherapy treatment. conditions: Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Feasibility randomised controlled trial using a 2:1 randomisation primaryPurpose: SUPPORTIVE_CARE masking: NONE maskingDescription: Not indicated for this feasibility study. count: 50 type: ESTIMATED name: Exercise name: Health Behaviour Change (Pedometer) measure: Feasibility: Recruitment rates measure: Feasibility: Adherence rates measure: Feasibility: Attendance rates measure: Feasibility: Retention Rates measure: Feasibility: Reason for drop0out measure: Cardiorespiratory Fitness measure: Muscular Strength measure: Body Mass Index measure: Mid-arm circumference measure: Waist Circumference measure: Bioimpedance Analysis measure: Health Related Quality of Life measure: Fatigue sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: St James's Hospital city: Dublin zip: 8 country: Ireland lat: 53.33306 lon: -6.24889 hasResults: False
|
<|newrecord|> nctId: NCT06280872 id: P2023/Neonat/PhyCordPrem briefTitle: Physiologically Based Cord Clamping To Improve Neonatal Outcomes In Moderate And Late Preterm Newborns acronym: PhyCordPrem overallStatus: RECRUITING date: 2024-02-19 date: 2026-01 date: 2026-07 date: 2024-02-28 date: 2024-03-05 name: Queen Fabiola Children's University Hospital class: OTHER name: The Belgian Kids Fund name: Fonds IRIS-Recherche name: Ars Statistica briefSummary: Before birth, the baby's lungs are filled with fluid and babies do not use the lungs to breathe, as the oxygen comes from the placenta. As delivery approaches, the lungs begin to absorb the fluid. After vaginal delivery, the umbilical cord is clamped and cut after a delay that allows some of the blood in the umbilical cord and placenta to flow back into the baby. Meanwhile, as the baby breathes for the first time, the lungs fill with air and more fluid is pushed out. However, it does not always work out that way.
|
A baby born prematurely may have breathing problems because of extra fluid staying in the lungs related to the immaturity of the lung structure. Thus, the baby must breathe quicker and harder to get enough oxygen enter into the lungs. The newborn is separated from the mother to provide emergency respiratory support. Although the baby is usually getting better within one or two days, the treatment requires close monitoring, breathing help, and nutritional help as the baby is too tired to suck and swallow milk. Sometimes, the baby cannot recover well and show greater trouble breathing needing intensive care. This further separates the mother and her baby. A possible mean to help the baby to adapt better after a premature birth while staying close to the mother is to delay cord clamping when efficient breathing is established, either spontaneously or after receiving breathing help at birth. In this study, we intend to test this procedure in moderate or late preterm infants and see whether the technique helps the baby to better adapt after birth and to better initiate a deep bond with the mother. conditions: Premature Birth conditions: Respiratory Distress Syndrome in Premature Infant conditions: Sepsis conditions: Intraventricular Hemorrhage of Prematurity conditions: Bronchodysplasia conditions: Jaundice studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 180 type: ESTIMATED name: Physiological Based Cord Clamping name: Differed Cord Clamping measure: Duration of non-invasive or invasive respiratory support. measure: Rate of neonatal mortality measure: Rate of neonatal resuscitation measure: Rate of neonatal respiratory morbidity measure: Number of admission to the NICU or special care baby unit measure: Length of hospitalization measure: Gestational age corrected at discharge measure: Changes in physiological variables during neonatal transition measure: Early neonatal parameters measure: Hemoglobin level measure: Bilirubin level measure: Occurrence of Neonatal adverse events measure: Biological markers of oxidative stress measure: Maternal perioperative parameters measure: Maternal postoperative hemoglobin level measure: Number of maternal adverse events measure: Maternal-infant bonding measure: Maternal-infant bonding measure: Maternal-infant bonding measure: Rate of Maternal-infant bonding measure: Rate of Maternal-infant bonding measure: Rate of Maternal-infant bonding measure: Maternal-infant bonding measure: Parental satisfaction survey measure: Child development assessment measure: Success of PBCC sex: ALL minimumAge: 32 Weeks maximumAge: 36 Weeks stdAges: CHILD facility: CHU Brugmann status: RECRUITING city: Brussels zip: 1020 country: Belgium name: Andrew CARLIN role: CONTACT phone: +3224773295 email: [email protected] name: Andrew CARLIN, MD role: PRINCIPAL_INVESTIGATOR lat: 50.85045 lon: 4.34878 facility: Hôpital Universitaire Des Enfants Reine Fabiola status: RECRUITING city: Brussels zip: 1020 country: Belgium name: Anna AMORUSO, MD role: CONTACT phone: +3224773250 email: [email protected] name: Anna AMORUSO role: PRINCIPAL_INVESTIGATOR lat: 50.85045 lon: 4.34878 hasResults: False
|
<|newrecord|> nctId: NCT06280859 id: 18784 briefTitle: Hoosier Sport: Developing and Implementing a Sustainable Campus-Community Partnership in Rural Indiana overallStatus: ACTIVE_NOT_RECRUITING date: 2024-02-20 date: 2024-05-30 date: 2024-06-10 date: 2024-02-28 date: 2024-03-15 name: Indiana University class: OTHER name: United States Department of Agriculture (USDA) briefSummary: The clinical trial aims to develop and pilot test a multilevel physical activity (PA) intervention called the Hoosier Sport program. The study follows a participatory co-design protocol involving youth, parents, and community leaders to provide direct input into the intervention's design. The ultimate goal is to contribute to health equity in the community by promoting sustainable physical activity. Hoosier Sport involves delivering enhanced physical education classes, teaching about nutrition and exercise, as well as developing leadership skills in middle school rural students.The intervention will last for 8-weeks with PE classes occur twice a week. Additionally, Hoosier Sport will create more opportunities for students to be active at school (e.g., in home room) through providing virtual classes and other activities. conditions: Cardiovascular Diseases conditions: Sedentary Behavior studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Students enrolled in physical education (PE) class will be eligible to enroll in the study, and serve as the intervention group. Those not enrolled in PE that semester will be recruited as the control group. primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 34 type: ACTUAL name: Hoosier Sport measure: Feasibility of Intervention Measure (FIM) measure: Acceptability of Intervention Measure (IAM) measure: Intervention Appropriateness Measure (AIM) measure: Daily Steps of Participants measure: Daily Moderate to Vigorous Physical Activity of Participants measure: Heart Rate of Participants measure: Blood Pressure of Participants measure: Basic Psychological Needs of Participants in Intervention Environment measure: Physical Literacy of Participants measure: Cardiovascular Fitness Levels of Participants measure: Muscular Endurance Levels of Participants measure: Self-Reported Weekly Moderate to Vigorous Physical Activity of Participants measure: Nutrition Knowledge of Participants measure: Policy, Systems, and Environmental Factors Influencing Participant Physical Activity and Nutrition Behavior. sex: ALL minimumAge: 9 Years maximumAge: 15 Years stdAges: CHILD facility: Indiana University city: Bloomington state: Indiana zip: 47405 country: United States lat: 39.16533 lon: -86.52639 hasResults: False
|
<|newrecord|> nctId: NCT06280846 id: P.T.REC/012/004878 briefTitle: High-intensity Versus Low-intensity Laser Acupuncture in Chronic, Non-specific Low Back Pain overallStatus: RECRUITING date: 2024-03-15 date: 2024-10-30 date: 2024-10-30 date: 2024-02-28 date: 2024-04-26 name: Cairo University class: OTHER name: King Khalid University briefSummary: The purpose of this study is to investigate the efficacy of high-intensity laser acupuncture versus low intensity laser acupuncture on peak torque of trunk extensors, fatigue of trunk extensors, back pain, ROM and function in patients with chronic nonspecific low back pain (CNLBP). conditions: Chronic Nonspecific Low-back Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: high-intensity laser acupuncture, low-intensity laser acupuncture and exercise therapy program primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: random generator whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: high-intensity laser acupuncture and Exercise therapy program name: low-intensity laser acupuncture and Exercise therapy program name: Sham laser acupuncture measure: peak torque measure: peak torque measure: Fatigue measure: Fatigue measure: Pain Intensity measure: Pain Intensity measure: lumbar flexion ROM assessment measure: lumbar flexion ROM assessment measure: Disability measure: Disability sex: ALL minimumAge: 20 Years maximumAge: 40 Years stdAges: ADULT facility: Doaa Ayoub Elimy status: RECRUITING city: Giza zip: 11251 country: Egypt name: Doaa A Elimy, lecturer role: CONTACT phone: 00201066474654 email: [email protected] lat: 30.00808 lon: 31.21093 hasResults: False
|
<|newrecord|> nctId: NCT06280833 id: 10001884 id: 001884-HG briefTitle: Care Choreographies and the Making of the Psychosocial in Genetic Counseling overallStatus: RECRUITING date: 2024-05-01 date: 2024-10-01 date: 2024-10-01 date: 2024-02-28 date: 2024-04-26 name: National Human Genome Research Institute (NHGRI) class: NIH briefSummary: Background:
|
Genetic counselors play a new and evolving role in medical care. Recent advances in genetic testing are changing many health care treatments, and genetic counselors play a key role in teaching people how their genes may affect both health and treatments. Genetic counselors may also help guide people through complex talks about their treatment risks; their chances for recovery; and their social and emotional health and wellbeing. Researchers want to learn more about the role genetic counselors play in health care.
|
Objective:
|
To observe how genetic counselors at NIH manage the social and psychological aspects of patient care.
|
Eligibility:
|
Genetic counselors who work at NIH. People aged 18 years or older who are scheduled to meet with one of these counselors are also needed.
|
Design:
|
An investigator will sit in on the session between the counselor and the participant. The investigator will take notes. The session will not be recorded. The investigator will leave at any point if asked.
|
The investigator will focus on talk about social and psychological care. That person will also listen to talk about risk; diagnosis; odds of recovery; and hope, grief, and loss. That person will note strategies that help the participant manage their emotions and how they perceive their risks.
|
Counselors may later have a 1-hour interview with the investigator. They will answer questions about their experiences as a care provider at NIH.
|
Participants will have only 1 session with the investigator. Counselors may have 4 to 10 sessions with an investigator over 8 months. conditions: Genetic Counselor studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 250 type: ESTIMATED measure: Care sex: ALL minimumAge: 18 Years maximumAge: 115 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National Human Genome Research Institute (NHGRI) status: RECRUITING city: Bethesda state: Maryland zip: 20892 country: United States name: Sara Hull, Ph.D. role: CONTACT phone: 301-435-8712 email: [email protected] lat: 38.98067 lon: -77.10026 hasResults: False
|
<|newrecord|> nctId: NCT06280820 id: 10001889 id: 001889-H briefTitle: Multi-Scale Analysis of Phenotypes in Heart Failure (MAP-HEART) overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2028-04-30 date: 2034-04-30 date: 2024-02-28 date: 2024-04-26 name: National Heart, Lung, and Blood Institute (NHLBI) class: NIH briefSummary: Background:
|
More than 6.5 million people in the United States live with heart failure (HF), and more than a million new cases are diagnosed each year. Treatments have improved in recent years, but researchers want to understand more about how HF develops. To do this, they need to compare blood and other samples from many people with HF.
|
Objective:
|
To collect blood and other samples from people with HF. These samples will be used to identify and study proteins and other factors that may lead to decreased heart function over time.
|
Eligibility:
|
People aged 18 years and older with heart failure.
|
Design:
|
Participants will be asked to join the study based on a review of their medical records.
|
They will have 1 study visit. They will provide a blood sample: About 3 tablespoons will be collected from a needle inserted into a vein.
|
Other tests are optional: Participants may provide urine and stool samples. They may have a cotton swab rubbed on the inside of the mouth to collect DNA.
|
Participants may also take 3 questionnaires. They will answer questions about dietary, social, and other factors that affect their health. Participants will receive compensation.
|
Researchers will follow the participants health by monitoring their medical records for up to 5 years. conditions: Heart Failure studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 2000 type: ESTIMATED measure: To study the association between multi-omics signatures with all-cause mortality measure: Clinical phenotypes defined by:Ejection Fraction (>=50 vs. < 50)NYHA (3-4 vs. 1-2) measure: To study the cross-sectional association between multi-omics signatures with clinical sub-phenotypes of heart failure sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National Heart, Lung and Blood Institute (NHLBI) city: Bethesda state: Maryland zip: 20892 country: United States name: Veronique Roger, M.D. role: CONTACT phone: 301-402-1715 email: [email protected] lat: 38.98067 lon: -77.10026 hasResults: False
|
<|newrecord|> nctId: NCT06280807 id: 10001617 id: 001617-E briefTitle: Observation of Environment and Reproductive-Endocrine Effects overallStatus: RECRUITING date: 2024-05-01 date: 2039-03-28 date: 2039-03-31 date: 2024-02-28 date: 2024-04-26 name: National Institute of Environmental Health Sciences (NIEHS) class: NIH briefSummary: Background:
|
Endocrine disorders occur when the glands that make hormones do not work properly. Hormones levels that are too high or too low can cause problems such as late or early puberty, irregular periods, and infertility. Environmental factors - including pollution; chemical exposure at home and work; foods; medicines; and sleep habits - may cause problems with the endocrine and reproductive systems.
|
Objective:
|
To learn how environmental factors may affect the endocrine and reproductive systems.
|
Eligibility:
|
Males or females, referring to sex assigned at birth, aged 8 years and older; they must have hypogonadism, infertility, or other reproductive disorders.
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.